1. ???? Basic Product Identification
Generic Name: Amiloride
Drug Class: Potassium-sparing diuretic
Therapeutic Category: Antihypertensive / diuretic agent
Common Forms: Tablets (often as hydrochloride salt)
Combination Use: Frequently with thiazide diuretics (e.g., HCTZ)
Key Function: Prevent potassium loss in urine
2. ???? Therapeutic Knowledge
Indications:
Hypertension (adjunct therapy)
Edema (heart failure, liver cirrhosis)
Prevention of hypokalemia (with other diuretics)
Clinical role:
Weak diuretic alone
Strong “potassium protection” agent in combination therapy
3. ⚙️ Mechanism of Action (MOA)
Blocks epithelial sodium channels (ENaC) in distal nephron
Reduces sodium reabsorption
Decreases potassium excretion
ENaC blockade→↓Na
+
WHO GMP amiloride API Manufacturer in Albania reabsorption→↓K
+
excretion
???? Key insight:
Works independently of aldosterone receptor
Different from spironolactone (no hormonal action)
4. ???? Pharmacokinetics (ADME)
Absorption
Oral bioavailability: ~50–70%
Distribution
Low to moderate protein binding
Metabolism
Minimal hepatic metabolism (mostly unchanged drug)
Excretion
Renal excretion (unchanged)
Half-life
~6–9 hours
5. ???? Dosage & Administration
Adults
5–10 mg once daily or divided doses
Combination therapy
Often 5 mg amiloride + hydrochlorothiazide combinations
⚠️ Key warning:
Risk of hyperkalemia increases in renal impairment
6. ???? Formulation Knowledge
Immediate release tablets
Fixed-dose combinations (FDCs) with thiazides
Formulation challenges:
Low-dose accuracy (5 mg strength)
Taste masking not critical (tablet form)
Stability in humid conditions important
Excipients:
Lactose / MCC
Starch (disintegrant)
Magnesium stearate
Film coating polymers
7. ???? Raw Materials Knowledge
Amiloride HCl API
Hydrochlorothiazide (for combination products)
Excipients: binders, disintegrants, lubricants
Film coating materials (HPMC, PEG)
8. ???? Manufacturing Process Knowledge
API Synthesis (high-level)
Pyrazine derivative formation
Functional group modification to create guanidinium-like structure
Salt formation (HCl)
Tablet Manufacturing:
Direct compression preferred
Wet granulation for FDC tablets
Critical blending uniformity due to low dose
9. ???? Analytical & QC Knowledge
Tests:
Assay (HPLC)
Content uniformity (critical)
Dissolution testing
Related substances (impurities)
Moisture content (LOD)
Stability-indicating methods
Key impurities:
Degradation of pyrazine ring derivatives
10. ???? Regulatory Knowledge
Approved globally as antihypertensive adjunct
USP / BP / IP monographs available
ANDA pathway for generics
FDC regulatory scrutiny (combination validation required)
Not a controlled substance
11. ????️ Storage & Stability
Store at 20–25°C
Protect from moisture
Stable under normal conditions
Avoid high humidity (tablet degradation risk in poor packaging)
12. ???? Packaging Knowledge
Alu-Alu blister preferred (moisture protection)
HDPE bottles with desiccant
Strip packs for low-cost markets
FDC blister packs widely used
13. ⚠️ Safety & Toxicology
Common adverse effects:
Hyperkalemia (major risk)
Nausea
Headache
Serious risk:
Cardiac arrhythmia due to high potassium
Contraindications:
Severe renal impairment
Hyperkalemia conditions
Drug interactions:
ACE inhibitors
ARBs
Potassium supplements
14. ???? Market & Commercial Knowledge
Generic cardiovascular diuretic market
High demand in:
Hypertension management (FDCs)
Heart failure adjunct therapy
Competitors:
Spironolactone
Triamterene
Strong FDC market in India & emerging economies
15. ⚖️ Intellectual Property (IP)
Original patents expired
FDC formulations may still be patented
Market driven by:
Combination therapy innovation
Brand positioning in hypertension segments
16. ???? Environmental & EHS Knowledge
Low environmental hazard compound
API synthesis waste requires standard chemical disposal
Tablet manufacturing dust control required
Minimal ecological impact compared to antibiotics or hormones
17. ???? Export Documentation Knowledge
GMP certificate
COA per batch
Stability data (ICH guidelines)
BE study (if required for FDC approval)
DMF (for API export markets)
Regulatory dossiers (ANDA/CTD format)
18. ???? Business Development Knowledge
High-volume generic cardiovascular drug
Strong demand in:
India
Africa
Southeast Asia
Strategy:
Focus on FDC (Amiloride + HCTZ)
Tender-based hospital supply
Competitive pricing essential
19. ???? Advanced Technical Knowledge
ENaC channel selectivity critical for potassium balance
Synergistic diuresis when combined with thiazides
Risk of hyperkalemia increases in renal dysfunction
Sodium-potassium balance is core therapeutic mechanism
20. ???? AI & Digital Knowledge (Modern Pharma)
AI applications:
Electrolyte imbalance prediction models
Hypertension control optimization
FDC formulation design simulation
Digital tools:
Clinical decision support systems (electrolyte alerts)
EHR-based potassium monitoring
Pharmacovigilance AI:
Hyperkalemia signal detection
21. ???????? Sales Team Product Knowledge Checklist
✔ Mechanism clarity (ENaC blocker)
✔ Potassium-sparing advantage explanation
✔ FDC positioning (with HCTZ)
✔ Hyperkalemia risk counseling
✔ Renal function awareness
✔ Competitor comparison (spironolactone)
✔ Hypertension guideline positioning
✔ Doctor objection handling
22. ???? Most Important Technical Documents
ANDA dossier (or CTD submission)
Stability studies (long-term + accelerated)
Dissolution profile reports
Assay & impurity validation reports
Bioequivalence study (if FDC)
GMP certificate
COA (batch release)
???? 23. Ultimate Pharma Product Mastery Summary
Amiloride is:
A potassium-sparing diuretic targeting ENaC channels
A key adjunct drug in hypertension and edema management
A product where electrolyte safety defines clinical success
A molecule where FDC strategy drives most commercial value
A stable, high-volume cardiovascular generic market drug